Skip to content
Partnership for Safe Medicines
  • News
    • Diabetes & Weight-loss Injectables
    • Peptides
    • Fake HIV Medications
      • Diverted HIV Meds on P2P platforms
    • PBMs
    • Botox / Botulism warning
    • Illegal Pill Presses
    • Poisonous cough syrup
    • Counterfeit Pill Crisis
  • Patients
    • About Counterfeits / Save Money Safely
    • Talk to Your Family
    • HIV/HEPC Patients
    • Foreign Online Pharmacies
    • Med spas
    • Mexican Pharmacies
  • Professionals
    • Law Enforcement
    • Pharmacists
    • Doctors
    • Prosecution Document Library
      • Cases we’re following
  • Policy
    • Publications
    • Pharmaceutical Border Security
    • Affordability Boards (PDABs)
    • Alternative funding programs (AFPs)
    • Mass compounding
    • Med spas
    • Illegal Pill Presses
    • Drug Importation
    • PBM under-reimbursement
    • FOIA-ed Materials
    • Events and briefings
  • About Us
    • Join Our Mailing List
    • PSM in the news
    • Press Releases
    • Members
    • PSM Leadership
    • Contact Us
Document Tags: 9:24-cv-00076-DLC, Complaint, G2 Telemedicine, GLP-1 lawsuit, Montana, Novo Nordisk, compounding, semaglutide
Return to list

United States District Court
District of Montana

Novo Nordisk Inc. v. JAE Medical PLLC dba G2 Telemedicine Weight Loss Clinic

Complaint

May 30, 2024

Read the document.

<a href="https://www.safemedicines.org/wp-content/uploads/2019/09/Novo-Nordisk-v-G2Telemedicine-Complaint.pdf">Novo Nordisk v G2 Telemedicine Weight Loss Clinic </a><br>Filed in Montana, May 30, 2024.
© 2003-2026 Partnership for Safe Medicines
Click here to contact us.
Facebook Twitter Linkedin Youtube Instagram Email
Scroll To Top